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General introduction 
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Preface: cancer and metastasis 
World Health Organization reported that cancer is the leading cause of mortality 
in human worldwide, with approximately 14 million new cases and 8.2 million cancer-
related deaths in 2012a. In the United States, approximately 40% of all people are 
expected to be diagnosed as a certain kind of cancer in their lifetime based on the data 
collected during 2009-2011, and five year survival rate of all cancer patients was 66.1% 
(2004-2010) according to Surveillance, Epidemiology and End Results Program, 
National Cancer Instituteb. 
 Cancer is also a leading cause of disease-related death in dogs, with nearly half 
of dogs aged older than ten years old dying from cancer (Withrow et al., 2012). In 
surveillance performed in Italy, 143 dogs in 100,000 dogs were estimated to develop 
malignant tumors in a year, which was comparable to that in human statistics (460.4 
cases / 100,000 men and women per year; 2007-20111) (Vascellari et al., 2009).  
 In both human and dog, there would be no doubt that systemic dissemination 
of cancer cells, or metastasis, is the end stage of cancer progression, turning the localized 
neoplasm into multiple organ-affecting and life-threatening disease (Clemente et al., 
                                               
a http://www.who.int/mediacentre/factsheets/fs297/en/ 
b http://seer.cancer.gov/ 
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2010; Fidler, 1978; Hanahan and Weinberg, 2011; Withrow et al., 2012). Cancer usually 
progress as follows; the cells start to invade surrounding extracellular matrix (ECM) and 
intravasate into systemic circulation. Then, the cells are trapped in capillary vessels, 
extravasate at the particular organs and finally colonize the secondary site with 
angiogenesis. Proliferated metastasis destructs normal function of the colonized organ. 
Since this formation of metastasis directly threatens survival of the cancer-bearing 
patients, priority of cancer treatment should be set on a control of the disseminating 
cancer cells. 
 
Cancer heterogeneity 
 Cancer does not consist of uniform cells but heterogeneous cells with 
spectrum of phenotypical diversity (Marte, 2013), and some specific group of 
cells in the heterogeneous population are thought to have metastatic 
potential (Dieter et al., 2011; Fidler, 1978; Fidler and Kripke, 1977; Marte, 
2013). It was reported that only one percent of malignant B16F1 melanoma 
cells injected into the portal vein formed liver macrometastasis (Luzzi et al., 
1998). Another report demonstrated that the success rate for brain 
macrometastasis formation of melanoma and lung carcinoma cells injected 
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into the carotid artery was 1.0-7.0% (Kienast et al., 2010). This cancer 
heterogeneity is explained by coexisting theories; cancer stem cell model, 
clonal evolution and heterogeneous microenvironment (Meacham and 
Morrison, 2013). 
 
Cancer stem cell model 
 Cancer stem cell (CSC) model explains horizontal heterogeneity of cancer cell 
phenotype. In CSC model, cancers are organized into a hierarchy of tumorigenic CSC 
and non-tumorigenic progenies (Fig. 1.1) (Kreso and Dick, 2014; Meacham and 
Morrison, 2013). This hierarchy is considered to be a reflection of normal tissue 
homeostasis because the same surface markers frequently could be utilized to 
characterize the stem cells of the normal tissue and CSCs in the cancer from the same 
tissue (Al-Hajj et al., 2003; Kreso and Dick, 2014). The demonstration that the LGR5 
molecule could be used for isolating the stem cells from the normal large intestine as 
well as the CSCs from the colorectal cancer tissues is an example (Barker, 2014). The 
CSC model has been suggested initially in a human hematological malignancy, followed 
by some types of solid cancers as well as malignancies in small animals (Al-Hajj et al., 
2003; Bhatia et al., 1997; Michishita et al., 2012). In CSC hierarchy theory, CSCs are 
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recognized as the only cells that can self-replicate, disseminate, repopulate and therefore 
finally form metastasis. Other progenies which compose of the bulk of the cancer mass 
are non-tumorigenic and non-metastatic. 
 
Clonal evolution 
Clonal evolution is the other model which explains cancer heterogeneity. 
Carcinogenesis is accomplished through serial genetic lesions comprised of mutations 
in oncogenes and tumor suppressor genes (Vogelstein et al., 2013; Vogelstein and 
Kinzler, 1993). A Fully developed cancer has genomic instability due to abnormal cell 
division and mutational inactivation of several DNA repair pathways, which might be 
acquired during carcinogenesis (Burrell and Swanton, 2014). This genomic instability 
may further accelerate the carcinogenesis process (Burrell et al., 2013). As a 
consequence, one cancer could contain a catalogue of up to thousands of genetic 
mutations (Vogelstein et al., 2013). However, some of these somatic mutations are not 
shared homogenously throughout cancer cells. Recent massive analysis using the 
advanced sequencing techniques has revealed that there are multiple subclones with 
different genetic lesions and distinct phenotypes in one cancer tissue. (Burrell and 
Swanton, 2014; Ding et al., 2012; Gerlinger et al., 2012; Walter et al., 2012). This kind 
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of clonal heterogeneity may develop during the cancer cell division where the impaired 
DNA repair or check systems allow to survive the cells with the novel genetic wounds. 
This notion of clonal diversity, or heterogeneity coincides with the previous observation 
in which not all the established subclones from one melanoma cell line had same 
metastatic potential as the parental cell line did (Fig. 1.2A) (Fidler, 1978). This result 
indicates that CSC theory does not explain cancer heterogeneity fully. In that article 
published more than three decades ago, the author questioned, “Does the process of 
metastasis represent the random survival of tumor cells, or does it result from the 
survival and growth of a specialized subpopulation of cells?” The recent technical 
advances could answer that the latter is true. The same discussion would be applied to 
the cancer relapse after failure of the chemotherapy. The pressure by the cytotoxic agents 
seem to allow the proliferation of the selective clones which are resistant to the therapy 
(Fig. 1.2B). Such heterogeneity is called as a clonal evolution after Darwinian selection 
or adaptive evolution. In this model, metastatic potential is considered to be restricted to 
the special clones that acquired metastatic potential by chance via some unique genetical 
change after carcinogenesis. 
 
Microenvironment  
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 Microenvironment surrounding the cancer cells could affect phenotype of 
cancer cells as well (Hanahan and Weinberg, 2011; Junttila and de Sauvage, 2013). 
Cancer formation involves co-evolution of surrounding ECM, vasculature, stroma and 
immune cells. Direct and indirect interaction between the cancer cells and the 
microenvironment could enable the cancer cells to proliferate, invade the surrounding 
tissue and evade immune surveillance, which give them the chance to survive and 
metastasize. The previous study which indicated the possibility of tumor infiltrating T 
lymphocyte to render the tumor cell malignant phenotype in canine mammary gland 
tumor tissues may be one example of interaction between tumor and surrounding 
components (Saeki et al., 2012). 
 
 These mechanisms which make the cancer cells diverse and heterogeneous are 
not mutually exclusive but can coexist in one context (Meacham and Morrison, 2013) 
(Fig. 1.3). Dieter et al. exhibited that different kind of CSCs are exist in colorectal cancer 
specimen and only subfraction of CSCs can survive serial passage in the immune-
deficient animals (Dieter et al., 2011). Metastatic formation was also accomplished by 
the subfraction of CSCs. They concentrated the CSC population by the suspension stem 
cell culture method and labeled each single cell by lentiviral transfection. After injection 
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of these CSCs into immune-deficient mouse and formation of systemic disease, clonal 
tracking was performed utilizing unique lentiviral insertion site in each clone. Their 
results showed that some CSCs can self-renew, repopulate progeny and form cancer 
mass, but do not metastasize. This observation is now understood as co-existence of 
clonal evolution and CSC hierarchy in the cancer. Phenotypically different clones could 
be maintained by each stem cell populations (Kreso and Dick, 2014; Meacham and 
Morrison, 2013). 
 
Bridging remarks to the thesis 
Canine mammary gland tumors (CMGTs) 
As mentioned above, cancer is a leading cause of death in elderly client-own 
dogs and metastatic spread of cancer often results in cancer-related death. Especially, 
CMGTs are the most common neoplasm in sexually intact female dogs and account for 
approximately half of all tumors that develop naturally in these animals (Dorn et al., 
1968; Rostami et al., 1994; Withrow et al., 2012). In addition, metastasis is a critical 
prognostic factor for CMGT (Chang et al., 2005). Overall survival after regional 
mastectomy of CMGT patients with macrometastasis in regional lymph nodes is 
significantly shorter (8.3 ± 6.8 months) than that in non-metastatic patients (19.0 ± 6.4 
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months) (Szczubiał and Łopuszynski, 2011). A series of 72 necropsies on CMGT 
patients showed that death was associated with systemic spread of metastatic lesions 
rather than local recurrence or invasion (Clemente et al., 2010). Therefore, prevention 
and control of metastasis is important for improving the prognosis of CMGT patients. 
 
Purpose of this study 
Accumulating evidences has suggested importance of control of metastatic cells 
in CMGT patients. However, the difference between metastatic cells and non-metastatic 
cells was still unclear in CMGT. Therefore, the way that we could specifically target 
metastatic cells has been not determined as well so far.  
The purpose of this thesis was to find metastatic CMGT cell specific inhibitory 
agents and clarify its mechanism for improvement of cancer treatment. For this purpose, 
in the chapter 2, I adopted an unbiased drug screening using the CMGT subcones with 
contrasting metastatic potential established in the previous study (Murai et al., 2012), 
and searched for metastatic clone selective inhibitors. In the chapter 3, clinical 
applicability of the identified metastatic clone-specific inhibitor was investigated.  
Furthermore, mainly in the chapter 3 and 4, in vitro mechanism of the action of 
the selected inhibitor was pursued. Further presentation, interpretation and discussion of 
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the experiments will be found in the following chapters. 
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Chapter 2 
 
Molecularly targeted drug screening  
by using metastatic and non-metastatic clones  
of canine mammary gland tumor cell line 
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Introduction 
 Understanding of the cancer biology is essential for development of the 
effective therapy. As discussed in the previous chapter, since most of the cancer mortality 
is attributed to the systemic spread of the cancer cells, including CMGT, the treatment 
focused on control of the metastatic cells will improve patient prognosis effectively.  
Previously, Murai et al. has cloned 23 subclones in total from the single 
established cell line (CHMp) which had been derived from a dog with inflammatory 
mammary carcinoma (Fig. 2.1) (Murai et al., 2012). Three of these subclones, CHMp-
5b, CHMp-11a and CHMp-13a, were transplanted into immune-deficient mice and they 
exhibited strikingly distinct behavior in the recipient animals; CHMp-5b formed huge 
primary tumors, CHMp-13a colonized as a slowly growing tumor which finally stopped 
to enlarge, and CHMp-11a behaved intermediately (Murai et al., 2012). Moreover, only 
CHMp-5b cells metastasized to the lung in an orthopedic injection model. These results 
were very similar to the previous observation about mouse melanoma cells (Fidler, 1978) 
(Fig. 1.2A), therefore clonal diversity with phenotypic difference was strongly indicated 
in canine mammary gland tumor (CMGT). Thus, it was suggested that metastatic clones 
in CMGT might be an effective therapeutic target and chemotherapy selective for these 
clones may improve treatment outcomes of CMGT. 
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 These phenotypical difference, or distinct metastatic potential, between clones 
was supposed to be derived from gain-of- or loss-of-function in some gene products as 
a consequence of the clonal evolution. Since such genetic changes may cause not only 
enhanced malignant behaviors of the cells but also changes in other vital cellular 
signaling or functions. Therefore, it was speculated that CHMp-5b clone may have 
selective vulnerabilities in its complicated cellular signaling network which the other 
CMGT clones or normal cells did not carry. A possible approach to inquire the 
vulnerability was an unbiased molecularly targeted drug screening. 
 In 2009, Gupta et al. reported a chemical agent screening using the induced 
CSC model (Gupta et al., 2009). They searched more than ten thousands compounds to 
find out selective inhibitors against the induced CSC cells. As a result, salinomycin, a 
coccidiostat, was picked up due to its more than one hundred in vitro selectivity against 
CSCs. Salinomycin actually exhibited anti-cancer activity in a xenograft model. It was 
of great interest that the exact mechanism of anti-tumor activity of salinomycin had been 
unclear for years until the numerous following studies revealed involvement in apoptosis, 
interference with drug efflux transporters, inhibition of oxidative phosphorylation or 
inhibition of Wnt signaling (Naujokat and Steinhart, 2012). In other example, Kitambi 
et al. reported specific growth inhibitors against human glioblastoma multiforme (GBM) 
20 
 
cells (Kitambi et al., 2014). They screened approximately one thousand small molecule 
inhibitors comparing human GBM cell lines with human fibroblasts, mouse embryonic 
stem cells, mouse glial cells and mouse neurons, and found that GBM cells were 
specifically vulnerable to the one compound which they named vaquinol. Vaquinol also 
showed anti-tumor effect against GBM cells in vivo without apparent toxicity. They 
further performed an unbiased short-hairpin RNA screening and concluded that anti-
tumor effect of vaquinol was mediated by activation of MKK4, which belongs to the 
stress/GPCR agonists/cytokine/growth factor-activated pathway. Clear mechanism of 
vaquinol is still not fully understood since there is only limited knowledge about the 
function of MKK4 molecule and its involvement in cancer. From these examples, an 
unbiased drug screening is considered to be one promising option to find out 
phenotypically distinct cell-specific vulnerability. 
The hypothesis was that the metastatic CMGT clone had a distinct phenotype 
and unique cellular signaling when compared to the clone with lower malignancy, and 
this, in turn, might result in differential sensitivity to particular drugs. The aim of this 
study was to screen a novel class of drugs against CMGT clones with different metastatic 
potentials to identify candidates for metastatic clone-specific chemotherapy. For that 
purpose, I first performed extensive expression analysis and phenotyping of two 
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previously established CMGT clonal cell lines. Next, an unbiased molecular targeting 
drug screening system was adopted to select agents that differentially affected the growth 
of the metastatic and non-metastatic clones. Finally, I explored the mechanism of action 
of the candidate drugs to gain insight into the specific pathways responsible for the 
observed differential effects. 
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本章の以降の内容は、学術論文として出版する計画があるため公表できない。
2年以内に公表予定。 
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Chapter 3 
 
Anti-tumor effect of metformin 
 in canine mammary gland tumor cells 
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本章の内容は、学術論文として出版する計画があるため公表できない。2 年以
内に公表予定。 
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Chapter 4 
 
Metformin-induced growth inhibition is attenuated  
by external NAD supplementation  
in metastatic CMGT cell line 
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本章の以降の内容は、学術論文として出版する計画があるため公表できない。
3年以内に公表予定。 
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Chapter 5 
 
General discussion and conclusion 
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AMPK is the molecule regarded as an energy sensor which has an important 
evolutionary role to tackle low nutrient supply, turning cellular metabolism into 
energy-sparing state (Foretz et al., 2014). Therefore, mTOR pathway inhibition and 
associated attenuation of cell proliferation in CHMp-13a would be one consequence of 
cellular response for restriction of energy consumption. However, with its protective 
role against energy shortage, AMPK is also known to improve cell survival under 
energy stress. The clear example has come from the liver kinase B1 (LKB1)-deficient 
mouse transgenic model (Shackelford et al., 2013). LKB1 molecule locates upstream 
of AMPK, and controls phosphorylation and activation of AMPK under energetic 
stress. In that study, combining LKB1 deficiency with KRAS-induced murine lung 
carcinoma model, the authors reported that LKB1 deficient tumor was more likely to 
strongly respond to phenformin treatment, which was the other biguanide derivative 
with similar function to metformin. Thus, it was concluded that cancer cells 
functionally deficient in AMPK activation may be not able to handle and suppress their 
energy consumption under energy-restricting circumstance, such as a biguanide 
treatment, resulting in fatal energy crisis.  
Other enhanced sensitivity to the biguanides has been recently reported in the 
mitochondrial respiratory complex 1-mutated or glucose incorporation-impaired cancer 
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cells (Birsoy et al., 2014). These cancer cells were also strikingly sensitive to low 
glucose condition. The authors concluded that the cancer cells with such deficiency 
were sensitive to the biguanide because their ATP production in mitochondria might be 
easily disrupted due to low reserve capacity of mitochondria (complex 1 deficiency) or 
substrate shortage (impaired glucose incorporation).  
However, high sensitivity to metformin and AMPK-independent cell cycle 
arrest observed in the metastatic CHMp-5b was not likely to be explained by 
functional AMPK deficiency, impaired glucose incorporation or intrinsic mitochondrial 
dysfunction, at least under 2 mM metformin treatment. In the serial experiments in this 
thesis, it was noticed that metformin could exert anti-proliferative effect at the 
concentration where mitochondrial ATP production was not yet disrupted. The 
suggested mechanisms for elevated sensitivity to the biguanides in the previous studies 
expect cellular ATP shortage and fatal energy crisis at the low drug concentration 
exposure, at which normal cells could keep ATP production with enhanced glucose 
utilization or reserve mitochondria function. Or sometimes, functionally normal cells 
also could reduce cellular ATP consumption by activating AMPK molecule to meet the 
restricted energy supply as CHMp-13a did. Therefore, it was speculated that decrease 
in mitochondrial ATP production should have become apparent under 2 mM-
32 
 
metformin treatment in the metastatic CHMp-5b if such explanation could be applied 
to. Our results in the subsequent experiment suggested cellular NAD deprivation as a 
novel key phenomenon on the exposure to metformin.  
 
It was of great interest that the identified selective anti-metastatic agents were 
inhibitors of the mitochondrial OXPHOS because one hallmark of the cancer cell was 
enhanced glycolytic activity regardless of the oxygen availability (Hanahan and 
Weinberg, 2011). This aerobic glycolysis or “Warburg effect” was discovered 
approximately one century ago by Otto Warburg (Weinhouse et al., 1956). This 
glycolytic character of the cancer cell even under the normoxic condition has been 
exploited successfully for the diagnostic imaging of cancer (such as 18Fluoro-
deoxyglucose positron emission tomography). In addition, several therapeutic approach 
targeting cancer glycolysis, such as glucose analogs, are currently under investigation 
(Ganapathy-Kanniappan and Geschwind, 2013; Granchi et al., 2014). Enhanced 
glycolysis is considered be beneficial for cancer cells because it could support cancer 
cell survival under hypoxic condition and supply more building blocks of the cellular 
component as intermediates from the enhanced pentose phosphate pathway. 
On the other hand, the recent studies also indicated the importance of OXPHOS 
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in cancer cells, especially in CSC populations (Birsoy et al., 2014; Pastò et al., 2014), 
indicating the significance of the mitochondria-targeting strategy for cancer 
management. These studies focused on ATP production from mitochondria and showed 
resistance of CSC populations to glucose-deprivation. The findings in this thesis may 
also indicate importance of the OXPHOS in the malignant population in the cancer from 
the view of proper recycling of NAD. Complicated cancer cell metabolism should be 
further evaluated taking tumor heterogeneity into account. 
 
In conclusion, in this thesis, it was suggested that MRCIs may serve as a 
metastatic clone specific agents. Clinical applicability of one such MRCI, metformin 
was also demonstrated. In addition, distinct cellular signaling or function at the 
OXPHOS was indicated between the metastatic and the non-metastatic clones. There 
still exists a gap between anti-tumor mechanism of metformin (and other MRCIs) and 
selective vulnerability of the metastatic clone, however, these novel findings, especially 
the involvement of NAD, would contribute to the understanding and future clinical 
application of metformin and other MRCIs. In human medicine, metformin has been 
attracting great attention as well due to the plenty of the reports which have demonstrated 
selective anti-tumor effect of the drug on CSC population, the other side of cancer 
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heterogeneity. Future study should be performed to identify the functional molecules 
which must connect fluctuation of NAD with the cell cycle machinery and may have 
relationship with cancer malignancy. We also should translate the findings in this thesis 
into future clinical application. 
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